Rare and unfavorable course of chronic myeloid leukemia – a case report and review of the literature
Authors:
P. Rohoň 1; V. Markuseková 1; E. Bojtárová 1; L. Sopko 1; I. Majeský 2; A. Žákovičová 3; Ľ. Majerová 3; L. Tatayová 3; A. Blahová 3; M. Krajčíková 3; A. Bátorová 1
Authors‘ workplace:
Klinika hematológie a transfúziológie LF UK, SZU a UN Bratislava, Slovensko
1; II. chirurgická klinika LF UK a UN Bratislava, Slovensko
2; Oddelenie lekárskej genetiky, Medirex, a. s., Slovensko
3
Published in:
Transfuze Hematol. dnes,29, 2023, No. 1, p. 40-49.
Category:
Case Reports
doi:
https://doi.org/10.48095/cctahd202340
Overview
Patients with chronic myeloid leukaemia (CML) in chronic phase have a life expectancy similar to the general population when treated with tyrosine kinase inhibitors. Despite these improvements, the major challenge for haematologists is to determine the optimal treatment approach in advanced CML phases (primary or therapy-induced and associated with clonal evolution). Advanced disease has varied clinical manifestations and may be associated with unusual and often life-threatening situations. We present here a rare case of continuous disease progression on tyrosine kinase inhibitor treatment with severe haemorrhagic manifestations in blast crisis, and posttransplant relapse. We also present a review of published literature.
Keywords:
chronic myeloid leukaemia – ponatinib – advanced phases of disease – intraabdominal bleeding – allogeneic stem cell transplantation
Sources
1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020; 95 (6): 691–709.
2. Chen Z, Cortes JE, Jorgensen JL, et al. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016; 41: 327–328.
3. Wang H, Cao F, Li J, et al. Intracerebral hemorrhage as the initial presentation of chronic myeloid leukemia: a case report and review of the literature. Front Neurol. 2020; 11: 571576.
4. Padmanabhan V, Shahin MM, Abdallah K. Chronic myeloid leukaemia manifesting as a gynecological emergency in a young woman. Int J Reprod Contracept Obstet Gynecol. 2017; 6 (8): 3655–3656.
5. Jafferbhoy S, Chantry A, Atkey N, et al. Spontaneous splenic rupture: an unusual presentation of CML. BMJ Case Rep. 2011; bcr0220113 879.
6. Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015; 2: e186-e193.
7. Čičátková P, Žáčková D. Vysazování inhibitorů tyrozinkináz u pacientů s chronickou myeloidní leukemií ve studiích a klinické praxi. Transfuze Hematol Dnes. 2020; 26 (4): 279–291.
8. Bonifacio M, Stagno F, Scaffidi L, et al. Management of chronic myeloid leukemia in advanced phase. Front Oncol. 2019; 25 (9): 1132.
9. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122: 872–884.
10. Hochhaus A, Baccarani M, Silver RT, et al. Chronic myelogenous leukemia. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34: 966–984.
11. Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112 (4): 1005-1012.
12. Hehlmann R, Saussele S, Voskanyan A, et al. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016; 29: 295–307.
13. Saxena K, Jabbour E, Issa G, et al. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021; 14: 94.
14. Žáčková D. Ponatinib v léčbě pacienta s lymfoblastickým zvratem chronické myeloidní leukemie – význam před- a potransplantačního podání inhibitorů tyrosinkinázy. In Rohoň P, et al. Hematologie a hematoonkologie v kazuistikách. Praha, Maxdorf 2020, 118–122.
15. Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015; 94 (S2): 107–121.
16. Vemulakonda SHP, Subramaniyan S, Jain A, et al. A rare case of spontaneous splenic rupture as the index presentation of chronic myeloid leukemia. Cureus. 2021; 13 (11): e19647.
17. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymph. 2000; 39: 1–18.
18. Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009; 115: 2482–2490.
19. Kartthik S, Mandal PK, Abdullah SM. An unusual cause of bleeding in a patient with chronic myeloid leukemia chronic phase. Case Rep Hematol. 2019; Article ID: 5674 193.
20. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011; 118 (26): 6760–6768.
21. Vinhas R, Lourenco A, Santos S, et al. A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms. Haematologica. 2018; 103 (11): e549–e552.
22. Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016; 127 (22): 2742–2750.
23. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011; 118 (5): 1208–1215.
24. Soverini S, Abruzzese E, Bocchia M, et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol. 2019; 12: 131.
25. Gaillard J-B, Arnould C, Bravo S, et al. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 2010; 9 (11): 3083–3089.
26. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018; 132: 393–404.
27. Demitrovičová Ľ, Chudej J, Mikušková E, et al. Odporúčania pre manažment pacientov s chronickou myelocytovou leukémiou v Slovenskej republike Onkol Supl. 2021; 16: S3–S22.
28. Cortes JE, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021; 138 (21): 2042–2050.
29. Kishida Y, Najima Y, Otsuka Y, et al. Post-transplant maintenance treatment with ponatinib for Philadelphia chromosome positive leukemia. Blood. 2019; 134: S5694.
30. Kucukyurt S, Kelezoglu A, Elverdi T, et al. Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis. Hematol Transfusion Cell Ther. 2021; 16: S2531–1379 (21) 00082–1.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue 1
Most read in this issue
- Recommendations of the Czech Society of Haematology for the diagnosis and treatment of immune thrombocytopenia in adults
- Recommendations for thrombotic risk stratification and targeted thromboprophylaxis in women during assisted reproduction
- Rare and unfavorable course of chronic myeloid leukemia – a case report and review of the literature
- Blast phase of chronic myeloid leukaemia